LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

According to TipRanks.com, Wright is a 5-star analyst with an average return of 12.3% and a 61.9% success rate. Wright covers the Healthcare sector, focusing on stocks such as Phibro Animal Health, ...

UnitedHealth shares continue to struggle after the company issued a fresh outlook for 2025, indicating revenue and adjusted ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...